Syndax Pharmaceuticals (SNDX) Reiterated at Buy by Stifel

June 3, 2026 7:00 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $46.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found